Progesterone protects ovarian cancer cells from cisplatin-induced inhibitory effects through progesterone receptor membrane component 1/2 as well as AKT signaling

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2488-2494

  Zhu, Xiaofei ^a   Han, Yue ^a   Fang, Zhuyuan ^a   Wu, Wenzhong ^a   Ji, Mingde ^a   Teng, Fengmeng ^a   Zhu, Wei ^b   Yang, Xuewen ^a   Jia, Xuemei ^b   Zhang, Chunbing ^a  

^a AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

AKT; Migration; Ovarian cancer; Progesterone; Progesterone receptor membrane component 1 2

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; MEMBRANE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN PGRMC1; PROTEIN PGRMC2; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL MIGRATION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEIN V-AKT; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PREGNANCY; PROGESTERONE; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION;

EID: 84885065598     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2680     Document Type: Article

References (39)

1. Salzberg M, Thurlimann B, Bonnefois H, et al: Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 68: 293-298, 2005.
2. O'Brien ME, Dowsett M, Fryatt I and Wiltshaw E: Steroid hormone profile in postmenopausal women with ovarian cancer. Eur J Cancer 30A: 442-445, 1994.
3. Halperin R, Hadas E, Langer R, Bukovsky I and Schneider D: Peritoneal fluid gonadotropins and ovarian hormones in patients with ovarian cancer. Int J Gynecol Cancer 9: 502-507, 1999.
4. Modugno F, Ness RB and Cottreau CM: Cigarette smoking and the risk of mucinous and nonmucinous epithelial ovarian cancer. Epidemiology 13: 467-471, 2002.
5. Franks AL, Lee NC, Kendrick JS, Rubin GL and Layde PM: Cigarette smoking and the risk of epithelial ovarian cancer. Am J Epidemiol 126: 112-117, 1987.
6. Green A, Purdie D, Bain C, Siskind V and Webb PM: Cigarette smoking and risk of epithelial ovarian cancer (Australia). Cancer Causes Control 12: 713-719, 2001.
7. Liu L, Wang J, Zhao L, et al: Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2. Endocrinology 150: 3186-3196, 2009.
8. Chen X, Cheng L, Jia X, et al: Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma-associated herpesvirus Kaposin A-mediated tumorigenesis of transformed fibroblasts in vitro as well as in nude and immunocompetent mice. Neoplasia 11: 1272-1284, 2009.
9. Tang Q, Qin D, Lv Z, et al: Herpes simplex virus type 2 triggers reactivation of Kaposi's sarcoma-associated herpesvirus from latency and collaborates with HIV-1 Tat. PLoS One 7: e31652, 2012.
10. Qin D, Feng N, Fan W, et al: Activation of PI3K/AKT and ERK MAPK signal pathways is required for the induction of lytic cycle replication of Kaposi's sarcoma-associated herpesvirus by herpes simplex virus type 1. BMC Microbiol 11: 240, 2011.
11. Albrecht C, Huck V, Wehling M and Wendler A: In vitro inhibition of SKOV-3 cell migration as a distinctive feature of progesterone receptor membrane component type 2 versus type 1. Steroids 77: 1543-1550, 2012.
12. Rodon J, Dienstmann R, Serra V and Tabernero J: Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10: 143-153, 2013.
13. Wu J, Chen C and Zhao KN: Phosphatidylinositol 3-kinass signalings as a therapeutic target for cervical cancer. Curr Cancer Drug Targets 13: 143-156, 2013.
14. Polak R and Buitenhuis M: The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood 119: 911-923, 2012.
15. Sun CC, Ramirez PT and Bodurka DC: Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 4: 18-29, 2007.
16. Tangjitgamol S, Manusirivithaya S, Khunnarong J, Jesadapatarakul S and Tanwanich S: Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int J Gynecol Cancer 19: 620-627, 2009.
17. Shanmughapriya S, Senthilkumar G, Vinodhini K, Das BC, Vasanthi N and Natarajaseenivasan K: Viral and bacterial aetiologies of epithelial ovarian cancer. Eur J Clin Microbiol Infect Dis 31: 2311-2317, 2012.
18. Rosa MI, Silva GD, de Azedo Simoes PW, et al: The prevalence of human papillomavirus in ovarian cancer: a systematic review. Int J Gynecol Cancer 23: 437-441, 2013.
19. Gonzalez ER: Estrogen, progesterone receptors in ovarian cancer. JAMA 245: 1626, 1981.
20. Yin G, Chen R, Alvero AB, et al: TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 29: 3545-3553, 2010.
21. Maccio A, Madeddu C, Massa D, et al: Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 106: 362-367, 2005.
22. Lee KB, Byun HJ, Park SH, Park CY, Lee SH and Rho SB: CYR61 controls p53 and NF-κB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett 315: 86-95, 2012.
23. Murdoch WJ, Van Kirk EA, Isaak DD and Shen Y: Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts. Gynecol Oncol 110: 251-255, 2008.
24. Seeger H, Wallwiener D and Mueck AO: Is there a protective role of progestogens on the proliferation of human ovarian cancer cells in the presence of growth factors? Eur J Gynaecol Oncol 27: 139-141, 2006.
25. Ho SM: Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 1: 73, 2003.
26. Fauvet R, Dufournet Etienne C, Poncelet C, Bringuier AF, Feldmann G and Darai E: Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. Oncol Rep 15: 743-748, 2006.
27. Syed V, Ulinski G, Mok SC, Yiu GK and Ho SM: Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61: 6768-6776, 2001.
28. Peluso JJ, Gawkowska A, Liu X, Shioda T and Pru JK: Progesterone receptor membrane component-1 regulates the development and cisplatin sensitivity of human ovarian tumors in athymic nude mice. Endocrinology 150: 4846-4854, 2009.
29. Peluso JJ: Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer. Steroids 76: 903-909, 2011.
30. Lenhard M, Tereza L, Heublein S, et al: Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer 12: 553, 2012.
31. Leite DB, Junqueira MG, de Carvalho CV, et al: Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer. Steroids 73: 676-680, 2008.
32. Gabra H, Watson JE, Taylor KJ, et al: Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res 56: 950-954, 1996.
33. Petz LN, Nardulli AM, Kim J, Horwitz KB, Freedman LP and Shapiro DJ: DNA bending is induced by binding of the glucocorticoid receptor DNA binding domain and progesterone receptors to their response element. J Steroid Biochem Mol Biol 60: 31-41, 1997.
34. Noguchi T, Kitawaki J, Tamura T, et al: Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women. J Steroid Biochem Mol Biol 44: 657-660, 1993.
35. Mifsud W and Bateman A: Membrane-bound progesterone receptors contain a cytochrome b5-like ligand-binding domain. Genome Biol 3: Research0068, 2002.
36. Szczesna-Skorupa E and Kemper B: Progesterone receptor membrane component 1 inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome P450 reductase. Mol Pharmacol 79: 340-350, 2011.
37. Oda S, Nakajima M, Toyoda Y, Fukami T and Yokoi T: Progesterone receptor membrane component 1 modulates human cytochrome p450 activities in an isoform-dependent manner. Drug Metab Dispos 39: 2057-2065, 2011.
38. Leake K, Singhal J, Nagaprashantha LD, Awasthi S and Singhal SS: RLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancer. PLoS One 7: e34582, 2012.
39. Kim TR, Cho EW, Paik SG and Kim IG: Hypoxia-induced SM22α in A549 cells activates the IGF1R/PI3K/Akt pathway, conferring cellular resistance against chemo- and radiation therapy. FEBS Lett 586: 303-309, 2012.